Home > Analyse
Actualite financiere : Actualite bourse

J&J: presents solid tumor studies

(CercleFinance.com) - Johnson & Johnson has announced the presentation of 11 solid tumor studies at the WCLC and ESMO 2024 conferences.
The studies will cover lung, bladder, prostate and colorectal cancers.

At WCLC, new data will highlight Rybrevant in combination with Lazcluze for EGFR-mutated lung cancer, as well as a comparison between Lazcluze and osimertinib.

Results will also include information on the reduction of infusion-related reactions with Rybrevant, and a comparison between subcutaneous and intravenous formulations of this treatment.


Copyright (c) 2024 CercleFinance.com. All rights reserved.